Schedule 13G/A Filing for Protalix BioTherapeutics, Inc.

MAK Capital Fund LP, MAK Capital One L.L.C., and Michael A. Kaufman (collectively, the "Reporting Persons") have filed a Schedule 13G/A regarding their beneficial ownership of Protalix BioTherapeutics, Inc. Common Stock. As of March 30, 2026, the Reporting Persons beneficially own 3,616,289 shares, representing 4.5% of the outstanding Common Stock. This ownership is based on a total of 80,421,181 shares outstanding as of November 1, 2025. The filing indicates that the Reporting Persons hold shared voting and dispositive power over these shares. MAK Capital Fund LP is a Bermuda limited partnership, MAK Capital One L.L.C. is a Delaware limited liability company, and Michael A. Kaufman is a U.S. citizen. The Reporting Persons certify that the securities were not acquired or held for the purpose of or with the effect of changing or influencing the control of the issuer.